RxDoctor Payments DataLook up a doctor →

Penny Burcham

Family · Oxford, MSNPI 1609967520

Payments from drug & device makers

$22,042in general payments, 2019–2025

Across 1,273 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$1K
  • Pfizer$1K
  • Amgen$1K
  • Jazz Pharmaceuticals Inc.$1K
  • UCB, Inc.$1K
  • plus $13K from 48 others

What the payments were for

  • Food & beverage$21,86099%
  • Education$1831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,042 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$120,317
Medicare patients
660
Services billed
2,466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sodium Oxybate12$229,281
EpidiolexCannabidiol (Cbd)28$221,264
XywavSodium,calcium,mag,pot Oxybate11$184,538
Kesimpta PenOfatumumab13$110,383
Aimovig AutoinjectorErenumab-Aooe117$97,481
VumerityDiroximel Fumarate11$91,246
AustedoDeutetrabenazine14$88,248
Nurtec OdtRimegepant Sulfate40$74,702
RytaryCarbidopa/Levodopa49$68,876
QuliptaAtogepant33$55,157
AptiomEslicarbazepine Acetate25$45,078
Emgality PenGalcanezumab-Gnlm37$37,658
FycompaPerampanel31$36,845
NeuproRotigotine31$36,799
Keppra XrLevetiracetam17$30,786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Neupro, Briviact, Vimpat, Nayzilam$1,032$110,28983 claims
BiogenVumerity$901$91,24611 claims
PfizerNurtec Odt, Lyrica$1,287$90,15553 claims
Teva Pharmaceuticals USA, Inc.Austedo$402$88,24814 claims
AbbVieQulipta, Ubrelvy$2,683$79,67649 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$394$71,21689 claims
Eisai Inc.Fycompa$419$36,84531 claims
SK Life Science, Inc.Xcopri$790$16,95814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →